Cyclophosphamide ‘offers no survival benefit’ with fibrosis flares
Adding the agent to high-dose glucocorticoids for flares of idiopathic pulmonary fibrosis might even be harmful, study suggests
Patients with an acute exacerbation of idiopathic pulmonary fibrosis (IPF) treated with high-dose glucocorticoids showed a trend towards increased mortality with added pulsed cyclophosphamide, researchers have found.
The French study findings provide evidence against the use of the IV therapy in such patients, the authors say.
